製品番号: HY-121118

Copy Link Print Information

Coronaridine

1 Cited Publications

カスタマーレビュー

Based on 1 publication(s) in Google Scholar

Coronaridine, an iboga type alkaloid, inhibits the wnt signaling pathway by decreasing β-catenin expression.

商品は「研究用試薬」です。人や動物の医療用・臨床診断用・食品用の製品ではありません。
研究用途以外に使用した場合、当社は一切の責任を負いかねます。

純度: 99.23%
CAS 番号: 467-77-6
分子式: C₂₁H₂₆N₂O₂
分子量:338.44

保管条件:

4°C, protect from light

* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)

Coronaridine 構造式

CAS 番号: 467-77-6

容量

価格（税別）

在庫状況

数量

Amount: USD 0.00

* アイテムを追加する前、数量をご選択ください

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

生物活性

製品説明

Coronaridine, an iboga type alkaloid, inhibits the wnt signaling pathway by decreasing β-catenin expression^[1].

Wnt アイソフォーム固有の製品をすべて表示 :

Cellular Effect

Cell Line	Type	Value	Description	References
A-431	ED₅₀	19.1 μg/mL Compound: 1	Cytotoxicity against human A431 cells by SRB assay Cytotoxicity against human A431 cells by SRB assay	[PMID: 7853002]
BC1 cell line	ED₅₀	7.5 μg/mL Compound: 1	Cytotoxicity against human BC1 cells by SRB assay Cytotoxicity against human BC1 cells by SRB assay	[PMID: 7853002]
Col2	ED₅₀	>20 μg/mL Compound: 1	Cytotoxicity against human Col2 cells by SRB assay Cytotoxicity against human Col2 cells by SRB assay	[PMID: 7853002]
DLD-1	IC₅₀	24.4 μM Compound: 3	Cytotoxicity against Wnt-dependent human DLD1 cells assessed as cell viability after 24 hrs by fluorescence assay Cytotoxicity against Wnt-dependent human DLD1 cells assessed as cell viability after 24 hrs by fluorescence assay	[PMID: 26231157]
HCT-116	IC₅₀	11.6 μM Compound: 3	Cytotoxicity against Wnt-dependent human HCT116 cells assessed as cell viability after 24 hrs by fluorescence assay Cytotoxicity against Wnt-dependent human HCT116 cells assessed as cell viability after 24 hrs by fluorescence assay	[PMID: 26231157]
HEK293	IC₅₀	31.7 μM Compound: 3	Cytotoxicity against HEK293 cells assessed as cell viability after 24 hrs by fluorescence assay Cytotoxicity against HEK293 cells assessed as cell viability after 24 hrs by fluorescence assay	[PMID: 26231157]
HEK-293T	IC₅₀	>40 μM Compound: 3	Cytotoxicity against HEK293T cells assessed as cell viability after 24 hrs by fluorescence assay Cytotoxicity against HEK293T cells assessed as cell viability after 24 hrs by fluorescence assay	[PMID: 26231157]
HeLa	EC₅₀	>40 μM Compound: 20	Inhibition of lysosomal acidification in human HeLa cells incubated for 3 hrs by LysoTracker Red DND-99 staining based array scan method Inhibition of lysosomal acidification in human HeLa cells incubated for 3 hrs by LysoTracker Red DND-99 staining based array scan method	[PMID: 32356659]
HT	ED₅₀	>20 μg/mL Compound: 1	Cytotoxicity against human HT cells by SRB assay Cytotoxicity against human HT cells by SRB assay	[PMID: 7853002]
KB	ED₅₀	13.6 μg/mL Compound: 1	Cytotoxicity against human KB cells by SRB assay Cytotoxicity against human KB cells by SRB assay	[PMID: 7853002]
KB-V1	ED₅₀	1.9 μg/mL Compound: 1	Cytotoxicity against human drug-resistant KBV1 cells by SRB assay in presence of vinblastine Cytotoxicity against human drug-resistant KBV1 cells by SRB assay in presence of vinblastine	[PMID: 7853002]
KB-V1	ED₅₀	11.2 μg/mL Compound: 1	Cytotoxicity against human drug-resistant KBV1 cells by SRB assay in absence of vinblastine Cytotoxicity against human drug-resistant KBV1 cells by SRB assay in absence of vinblastine	[PMID: 7853002]
LNCaP	ED₅₀	10.7 μg/mL Compound: 1	Cytotoxicity against human LNCAP cells by SRB assay Cytotoxicity against human LNCAP cells by SRB assay	[PMID: 7853002]
Lu1	ED₅₀	10.9 μg/mL Compound: 1	Cytotoxicity against human Lu1 cells by SRB assay Cytotoxicity against human Lu1 cells by SRB assay	[PMID: 7853002]
P388	ED₅₀	3.8 μg/mL Compound: 1	Cytotoxicity against mouse P388 cells after 48 hrs by SRB assay Cytotoxicity against mouse P388 cells after 48 hrs by SRB assay	[PMID: 7853002]
RAW264.7	IC₅₀	25.5 μM Compound: 10	Anti-inflammatory activity in mouse RAW264.7 cells assessed as LPS-stimulated inhibition of nitric oxide production incubated simultaneously with LPS for 24 hrs by Griess reagent based assay Anti-inflammatory activity in mouse RAW264.7 cells assessed as LPS-stimulated inhibition of nitric oxide production incubated simultaneously with LPS for 24 hrs by Griess reagent based assay	[PMID: 26024020]
RKO	IC₅₀	>40 μM Compound: 3	Cytotoxicity against Wnt-independent human RKO cells assessed as cell viability after 24 hrs by fluorescence assay Cytotoxicity against Wnt-independent human RKO cells assessed as cell viability after 24 hrs by fluorescence assay	[PMID: 26231157]
SK-MEL-2	ED₅₀	>20 μg/mL Compound: 1	Cytotoxicity against human SK-MEL-2 cells by SRB assay Cytotoxicity against human SK-MEL-2 cells by SRB assay	[PMID: 7853002]
SW480	IC₅₀	10.4 μM Compound: 3	Cytotoxicity against Wnt-dependent human SW480 cells assessed as cell viability after 24 hrs by fluorescence assay Cytotoxicity against Wnt-dependent human SW480 cells assessed as cell viability after 24 hrs by fluorescence assay	[PMID: 26231157]
U-373MG ATCC	ED₅₀	12 μg/mL Compound: 1	Cytotoxicity against human U373 cells by SRB assay Cytotoxicity against human U373 cells by SRB assay	[PMID: 7853002]
ZR-75-1	ED₅₀	>20 μg/mL Compound: 1	Cytotoxicity against human ZR-75-1 cells by SRB assay Cytotoxicity against human ZR-75-1 cells by SRB assay	[PMID: 7853002]

体外実験

Coronaridine (0-40 μM; 24 hours) is against non-cancer cells with IC₅₀ values >40 μM. It agaisnt wnt-dependent cells with IC₅₀ values of 10.4, 11.6 and 24.4 μM for SW480, HCT116 and DLD1cells, respectively^[1].
Coronaridine (0-40 μM; 24 hours) inhibits β-catenin expression, but the protein levels of p-β--catenin at Ser33, Ser37, and Thr41 and p-β-catenin at Ser 45 [p-b-catenin (S45)] are unchanged^[1].
In whole-cell patch clamp recordings,Catharanthine (1-300 μM) are respectively co-applied with GABA at concentrations corresponding to the EC₃₀ value for each receptor subtype. Both congeners potentiated different GABAARs in a concentration-dependent manner^[2].
At higher concentrations, however, Catharanthine starts to inhibit GABA-activated currents due to the reduced amplitude and rebound current, where the threshold concentration depended on the receptor subtype (e.g., > 30 μM for hα1β2; > 100 μM for hα1β2γ2 and hα2β2γ2). The PAM activity of Catharanthine's are depended on the receptor subtype: hα1β2 (4.6±0.8 μM), >hα2β2γ2 (12.6±3.8 μM), hα1β2γ2 (14.4 ± 4.6 μM)^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

化学情報

CAS 番号 467-77-6
性状 Solid
分子量 338.44
分子式 C₂₁H₂₆N₂O₂
Color White to off-white
SMILES

COC([C@]12[C@@]3([H])[N@@](CCC4=C2NC5=CC=CC=C45)C[C@@](C[C@@H]3CC)([H])C1)=O
Structure Classification
- Alkaloids
- Indole Alkaloids
Initial Source
輸送条件

Room temperature in continental US; may vary elsewhere.
保管条件

4°C, protect from light

* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)

Publications (1)

All

Sort by:

Journal Impact Factor

Brain Behav

EMX1 functions as a tumor inhibitor in spinal cord glioma through transcriptional suppression of WASF2 and inactivation of the Wnt/β-catenin axis. [Abstract]

2022 Jul 18;e2684. PMID: 35849030

溶剤 & 溶解度

体外:

DMSO : 50 mg/mL (147.74 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

2.9547 mL

14.7737 mL

29.5473 mL

5 mM

0.5909 mL

2.9547 mL

5.9095 mL

10 mM

0.2955 mL

1.4774 mL

2.9547 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

モル濃度計算機

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

濃度濃度

体積体積

分子量分子量

希釈計算機

濃度 _(開始) × 体積 _(開始) = 濃度 _(終了) × 体積 _(終了)

濃度 _(開始) 濃度 _(開始)

体積 _(開始) 体積 _(開始)

濃度 _(終了) 濃度 _(終了)

体積 _(終了) 体積 _(終了)

体内:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 90% Corn Oil

Solubility: ≥ 1.25 mg/mL (3.69 mM); Clear solution

This protocol yields a clear solution of ≥ 1.25 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (12.5 mg/mL) to 900 μL Corn oil, and mix evenly.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage Dosage
mg/kg
Animal Weight (Per Animal) Animal Weight (Per Animal)
g
Dosing Volume (Per Animal) Dosing Volume (Per Animal)
μL
Number of Animals Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

%
DMSO +

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
%
+
+
%
Tween-80 + +
%
Saline +

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Working solution concentration: 0.22 mg/mL

純度とドキュメンテーション

バッチを選択:

純度: 99.98%

Assay: 99.98%

ee.: 99.98%

データシート (279 KB)
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Korean - KR (251 KB)
- Portuguese - PT (251 KB)
COA (2659 KB)
元素分析報告書 (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
取扱説明書 (2659 KB)

参考文献

[1]. Kensuke Ohishi, et al. Coronaridine, an iboga type alkaloid from Tabernaemontana divaricata, inhibits the Wnt signaling pathway by decreasing β-catenin mRNA expression. Bioorg Med Chem Lett. 2015 Sep 15;25(18):3937-40. [Content Brief]

[2]. Hugo R Arias, et al. Coronaridine congeners potentiate GABA A receptors and induce sedative activity in mice in a benzodiazepine-insensitive manner. Prog Neuropsychopharmacol Biol Psychiatry. 2020 Jul 13;101:109930 [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO	1 mM	2.9547 mL	14.7737 mL	29.5473 mL	73.8683 mL
	5 mM	0.5909 mL	2.9547 mL	5.9095 mL	14.7737 mL
	10 mM	0.2955 mL	1.4774 mL	2.9547 mL	7.3868 mL
	15 mM	0.1970 mL	0.9849 mL	1.9698 mL	4.9246 mL
	20 mM	0.1477 mL	0.7387 mL	1.4774 mL	3.6934 mL
	25 mM	0.1182 mL	0.5909 mL	1.1819 mL	2.9547 mL
	30 mM	0.0985 mL	0.4925 mL	0.9849 mL	2.4623 mL
	40 mM	0.0739 mL	0.3693 mL	0.7387 mL	1.8467 mL
	50 mM	0.0591 mL	0.2955 mL	0.5909 mL	1.4774 mL
	60 mM	0.0492 mL	0.2462 mL	0.4925 mL	1.2311 mL
	80 mM	0.0369 mL	0.1847 mL	0.3693 mL	0.9234 mL
	100 mM	0.0295 mL	0.1477 mL	0.2955 mL	0.7387 mL

Keywords

Coronaridine

1 Cited Publications

100 mg お問い合わせ

Subscribe to the

MedChemExpress

Newsletter

製品名:
製品番号:
数量:
日本の代理先をお選びください:

製品名:
CAS 番号:
生物種:
純度:
数量:

Coronaridine

MCE Bioactive Compound Library

Natural Product Library Plus

MedChemExpress（MCE）の使用を引用している文献 Coronaridine

Wnt アイソフォーム固有の製品をすべて表示

生物活性

化学情報

Publications (1)

溶剤 & 溶解度

純度とドキュメンテーション

参考文献

Help & FAQs

Complete Stock Solution Preparation Table

Coronaridine

MCE Bioactive Compound Library

Natural Product Library Plus

MedChemExpress（MCE）の使用を引用している文献 Coronaridine

Wnt アイソフォーム固有の製品をすべて表示

生物活性

化学情報

Publications (1)

溶剤 & 溶解度

純度とドキュメンテーション

参考文献

Help & FAQs

Complete Stock Solution Preparation Table

Coronaridine 関連分類

HY-121118 関連分類